Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.

 

Category: Pharmacology

​​COVID-19 Therapeutics Thr​esholds, Orders, and Replenishment by Jurisdiction

On April 25, 2022, the distribution process for COVID-19 therapeutics to state and territorial health departments transitioned from the previous allocation process to one that more closely aligns with the allocation and ordering process for vaccines. 

   Estimated Time: Administration, COVID-19, Economics

NIH Resource: Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications

Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein inhibitor, is coadministered with nirmatrelvir to increase the blood concentration of nirmatrelvir, thereby making it effective against SARS-CoV-2. Ritonavir may also increase blood concentrations of ...

   Estimated Time: Antivirals, COVID-19

FDA Updates Sotrovimab Emergency Use Authorization

The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022,  estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider...

   Estimated Time: COVID-19, Pharmacology

New Paxlovid Dose Pack Author​ized by FDA

On April 14, 2022, the FDA revised the Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA. As a...

   Estimated Time: COVID-19, Pharmacology

Fact Sheet: COVID-19 Test to Treat

Through this program, people are able to get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a health care provider, and have their prescription filled all at one location. These “One-Stop Test to Treat” sites are availab...

   Estimated Time: Antivirals, Coronavirus, COVID-19, Therapies

Proning in COVID-19 Acute Respiratory Distress Syndrome: Role of Paralytics

From Critical Care Explorations The authors studied impact of paralysis on prone-induced gas exchange improvements and provider attitudes regarding paralytics.

   Estimated Time: 11:32 ARDS, Coronavirus, COVID-19, Proning

FDA Resource: Fact Sheet for Healthcare Providers: Emergency Use Authorization for Bebtelovimab

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of bebtelovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at l...

   Estimated Time: Coronavirus, COVID-19, Therapies

WHO Resource: WHO recommends two new drugs to treat COVID-19

WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be. The first drug, baricitinib, is strongly recommended for pat...

   Estimated Time: Coronavirus, COVID-19

HHS Resource: Federal Response to COVID-19 - Therapeutics Clinical Implementation Guide

HHS Presentation - Topics include: Introduction to COVID-19 Outpatient Therapeutics & Product Selection, Tools to Assist in COVID-19 Outpatient Therapeutic Selection, Overview of Emergency Use Authorizations, Oral Antiviral Indications and Dosing, Provider and Patient EU...

HHS Resource: COVID-19 Therapeutics Locator

The national map below displays public locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authority. The locations displayed in the locator have reported stock...

NIH Resource: The COVID-19 Treatment Guidelines Panel’s Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints

The COVID-19 Treatment Guidelines Panel (the Panel) has recommended several therapeutic agents for the treatment and prevention of SARS-CoV-2 infection in individuals who are at high risk for progression to severe COVID-19. These anti-SARS-CoV-2 therapeutics are of greatest be...

WHO Resource: WHO Therapeutics and COVID-19: living guideline

The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via ...

   Estimated Time: Coronavirus, COVID-19, Therapies

FDA Resource: Paxlovid received EUA approval from the FDA

December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years o...

   Estimated Time: Coronavirus, COVID-19, Therapies

FDA Resource: Molnupiravir received EUA approval from the FDA

The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir sh...

   Estimated Time: Coronavirus, COVID-19, Therapies

Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group

From Critical Care Explorations . In this study the authors found that hospital variation in the use of repurposed medications varied widely across hospitals early in the pandemic and later converged with the emergence of randomized clinical trials. 

   Estimated Time: 22:39 min Coronavirus, COVID-19

Current Approved Therapies for COVID-19

Stay up to date on the mass vaccination efforts in the United States with this SCCM webcast. Thought leaders will address current COVID-19 variants and vaccine efficacy and review pediatric vaccination considerations. This webcast is the second in a series of updates that SCCM...

   Estimated Time: 1:01:15 Coronavirus, COVID-19, Therapies

COVID-19 Vaccine Update

Stay up to date on the mass vaccination efforts in the United States with this FREE SCCM webcast. Thought leaders will address current COVID-19 variants and vaccine efficacy and review pediatric vaccination considerations. This webcast is the second in a series of updates that...

   Estimated Time: 1:02:27 Coronavirus, COVID-19, Vaccines

Critical Impact: COVID-19: Highlights Session 1

This webinar covers highlights from the Critical Impact: Clinical Practice course.

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial

From Critical Care Medicine .  In this study, the authors explored candidate prognostic and predictive biomarkers identified in retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, ferritin, lymphocytes, monocytes, neutrophils, D-dime...

   Estimated Time: 27:41 min Coronavirus, COVID-19

UCHealth COVID-19 Pharmacotherapy Guidance

This community developed resource is a quick reference guide for utlization of various COVID-19 pharmacotherapies.

   Estimated Time: 18:21 min Coronavirus, COVID-19, Therapies